RxDoctor Payments Data

David Patterson, DO

Family Medicine · Flat Rock, MINPI 1881682821

Payments from drug & device makers

$15,147in general payments, 2019–2025

Across 912 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$1K
  • Pfizer$898
  • GSK$817
  • plus $8K from 51 others

What the payments were for

  • Food & beverage$15,03699%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)105$1,811
Lilly USA, LLC87$1,158
Boehringer Ingelheim63$1,060
Novo Nordisk67$1,022
Pfizer51$898
GSK49$817
Amgen(2 entities)31$800
Kowa Pharmaceuticals America, Inc.91$711
Johnson & Johnson(2 entities)36$659
AstraZeneca(2 entities)29$484
Otsuka America Pharmaceutical, Inc.30$450
Ardelyx, Inc.14$429
Idorsia Pharmaceuticals US Inc17$372
Teva Pharmaceuticals USA, Inc.19$367
Exact Sciences18$334
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$285
Sanofi11$271
Regeneron Healthcare Solutions, Inc.17$262
Bayer14$257
Sanofi-aventis U.S. LLC10$229
E.r. Squibb & Sons, L.L.C.11$204
Mylan Specialty L.p.9$164
Smith+Nephew2$161
Amarin Pharma, Inc.11$157
Takeda Pharmaceuticals U.S.A., Inc.11$156
Biohaven Pharmaceutical Holding Company Ltd.7$142
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$141
Acadia Pharmaceuticals Inc5$128
Axsome Therapeutics, Inc.6$112
Merck7$105
Astellas Pharma US Inc6$94
Abbott6$91
Dexcom, Inc.5$89
Novartis4$65
Biohaven Pharmaceuticals, Inc.4$63
Lundbeck LLC3$60
Viatris Specialty LLC3$55
OWP Pharmaceuticals, Inc.3$50
Sanofi Pasteur Inc.3$45
Seqirus USA Inc2$40
Corcept Therapeutics2$37
Medicure Pharma Inc.2$34
Inspire Medical Systems, Inc.1$30
Ironshore Pharmaceuticals Inc.2$26
Ultragenyx Pharmaceutical Inc.1$24
Supernus Pharmaceuticals, Inc.1$22
Esperion Therapeutics, Inc.1$21
Dynavax Technologies Corporation1$20
Phadia US Inc.1$20
Endo Pharmaceuticals Inc.1$20
Sunovion Pharmaceuticals Inc.1$16
Verona Pharma, Inc.1$16
Gilead1$14
Dermira, Inc.1$14
Eisai Inc.1$13
Alfasigma USA, Inc.1$12
Circassia Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,147 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$110,317
Medicare patients
150
Services billed
1,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin102$97,667
XareltoRivaroxaban107$74,698
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$73,717
EliquisApixaban55$49,678
RybelsusSemaglutide25$45,887
JanuviaSitagliptin Phosphate23$25,414
FarxigaDapagliflozin Propanediol24$20,089
TradjentaLinagliptin13$18,792
TrulicityDulaglutide17$17,946
OzempicSemaglutide15$17,476
MounjaroTirzepatide15$15,461
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$12,129
EntrestoSacubitril/Valsartan15$11,476
Pitavastatin Calcium20$9,764
BelsomraSuvorexant21$9,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$1,060$116,459115 claims
GSKTrelegy Ellipta, Arexvy, Incruse Ellipta, Shingrix$817$90,118155 claims
Johnson & JohnsonXarelto$659$74,698107 claims
Novo NordiskRybelsus, Ozempic$1,022$63,36340 claims
PfizerEliquis$898$49,67855 claims
MerckJanuvia, Belsomra$105$35,01744 claims
Lilly USA, LLCTrulicity, Mounjaro$1,158$33,40732 claims
AstraZenecaFarxiga$484$20,08924 claims
NovartisEntresto$65$11,47615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Flat Rock

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →